(Q34785883)

4 August 2017

1 reference

title

Alemtuzumab in T-cell malignancies (English)

1 reference

4 August 2017

3

Daniel Catovsky

1 reference

4 August 2017

1

Claire E Dearden

1 reference

4 August 2017

2

Estella Matutes

1 reference

4 August 2017

publication date

1 January 2002

1 reference

4 August 2017

1 reference

4 August 2017

volume

19 Suppl

1 reference

4 August 2017

page(s)

S27-32

1 reference

In vivo 'Purging' of residual disease in CLL with Campath-1H

4 August 2017

cites work

1 reference

https://pubmed.ncbi.nlm.nih.gov/12180489

12 December 2020

Effect of Campath-1H antibody on human hematopoietic progenitors in vitro

1 reference

https://pubmed.ncbi.nlm.nih.gov/12180489

12 December 2020

High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H

1 reference

https://pubmed.ncbi.nlm.nih.gov/12180489

12 December 2020

Indolent course as a relatively frequent presentation in T-prolymphocytic leukaemia. Groupe Français d'Hématologie Cellulaire

1 reference

https://pubmed.ncbi.nlm.nih.gov/12180489

12 December 2020

Treatment of T-cell prolymphocytic leukemia with human CD52 antibody

1 reference

https://pubmed.ncbi.nlm.nih.gov/12180489

12 December 2020

Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype

1 reference

https://pubmed.ncbi.nlm.nih.gov/12180489

12 December 2020

Emerging applications of recombinant human granulocyte-macrophage colony-stimulating factor

1 reference

https://pubmed.ncbi.nlm.nih.gov/12180489

12 December 2020

Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/12180489

12 December 2020

Inactivation of the ATM gene in T-cell prolymphocytic leukemias.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12180489

12 December 2020

CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/12180489

12 December 2020

The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype

1 reference

https://pubmed.ncbi.nlm.nih.gov/12180489

12 December 2020

Subcutaneous CAMPATH-1H in fludarabine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukaemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/12180489

12 December 2020

Differential response in a patient treated with Campath-1H monoclonal antibody for refractory non-Hodgkin lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/12180489

12 December 2020

Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H

1 reference

https://pubmed.ncbi.nlm.nih.gov/12180489

12 December 2020

ATM is usually rearranged in T-cell prolymphocytic leukaemia.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12180489

12 December 2020

Remission Induction in Patients with Lymphoid Malignancies Using Unconjugated CAMPATH-1 Monoclonal Antibodies.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12180489

12 December 2020

Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/12180489

12 December 2020

Identifiers

DOI

10.1385/MO:19:2S:S27

1 reference

Dimensions Publication ID

4 August 2017

1011402294

0 references

1 reference